Search Within

Gary Schwartz

  1. "Epidemiology and Biostatistics"
Formats
  1. Journal Article (38)
  2. Meeting Abstract (31)
Groups
  1. Epidemiology and Biostatistics (69)
  2. Biostatistics Service (68)
  3. Department of Medicine (59)
  4. Solid Tumor Oncology Division (58)
  5. Center for Pancreatic Cancer Research (30)
  6. GSK Faculty (28)

More Groups

People
  1. Richard Carvajal (30)
  2. Mithat Gonen (22)
  3. Manish Shah (21)
  4. Li-Xuan Qin (19)
  5. Mark Dickson (19)
  6. David Kelsen (17)

More People

Years
  1. 2016 (1)
  2. 2015 (1)
  3. 2014 (5)
  4. 2013 (15)
  5. 2012 (8)
  6. 2011 (5)

More Years

Publications
  1. Journal of Clinical Oncology (30)
  2. Clinical Cancer Research (13)
  3. Cancer Chemotherapy and Pharmacology (3)
  4. Cancer Research (3)
  5. Cancer (2)
  6. JAMA - Journal of the American Medical Association (2)

More Publications

Publishers
  1. American Society of Clinical Oncology (30)
  2. American Association for Cancer Research (18)
  3. Springer (4)
  4. American Medical Association (2)
  5. Elsevier Inc. (2)
  6. Elsevier Science, Inc. (2)

More Publishers

Results (69)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Poor prognostic features in angiosarcoma: A single institution retrospective study of 324 patients
    Meeting Abstract

    D'Angelo, S. P.; Moraco, N. H.; Qin, L. X.; Kuk, D.; Carvajal, R. D.; Dickson, M. A.; Gounder, M. M.; Keohan, M. L.; Antonescu, C. R.; Singer, S.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • ABT-888 plus bendamustine is safe and has shown preliminary efficacy in patients with lymphoma
    Meeting Abstract

    Gerecitano, J. F.; Schwartz, G. K.; Carvajal, R.; Fury, M.; Konner, J.; Hyman, D. M.; Gounder, M.; Gajria, D.; Teitcher, J.; Zhang, Z.; more...
    Blood (2013)

    Fulltext@MSK | Save
  • Immunologic responses to xenogeneic tyrosinase DNA vaccine administered by electroporation in patients with malignant melanoma
    Journal Article

    Yuan, J.; Ku, G. Y.; Adamow, M.; Mu, Z.; Tandon, S.; Hannaman, D.; Chapman, P.; Schwartz, G.; Carvajal, R.; Panageas, K. S.; more...
    Journal for ImmunoTherapy of Cancer (2013)

    Fulltext@MSK | Save
  • Phase II study of selumetinib (sel) versus temozolomide (TMZ) in gnaq/Gna11 (Gq/11) mutant (mut) uveal melanoma (UM)
    Meeting Abstract

    Carvajal, R. D.; Sosman, J. A.; Quevedo, F.; Milhem, M. M.; Joshua, A. M.; Kudchadkar, R. R.; Linette, G. P.; Gajewski, T.; Lutzky, J.; Lawson, D. H.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Phase II trial of MEK inhibitor selumetinib (AZD6244) in patients with BRAFV600E/K- or NRAS-mutated melanoma
    Meeting Abstract

    Catalanotti, F.; Solit, D. B.; Pulitzer, M. P.; Berger, M. F.; Scott, S. N.; Iyriboz, T.; Lacouture, M. E.; Panageas, K. S.; Wolchok, J. D.; Carvajal, R. D.; more...
    Cancer Research (2013)

    Fulltext@MSK | Save
  • Final results of sequential phase 2 studies of palbociclib (PD0332991) in CDK4-amplified liposarcoma
    Meeting Abstract

    Dickson, M.; Tap, W. D.; Antonescu, C. R.; Landa, J.; Qin, L. X.; Crago, A. M.; Singer, S.; Schwartz, G. K.
    European Journal of Cancer (2013)

    Fulltext@MSK | Save
  • High-risk features in radiation-associated breast angiosarcomas
    Journal Article

    D'Angelo, S. P.; Antonescu, C. R.; Kuk, D.; Qin, L.; Moraco, N.; Carvajal, R. D.; Chi, P.; Dickson, M. A.; Gounder, M.; Keohan, M. L.; more...
    British Journal of Cancer (2013)

    Fulltext@MSK | Save
  • Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma
    Journal Article

    Dickson, M. A.; Tap, W. D.; Keohan, M. L.; D'Angelo, S. P.; Gounder, M. M.; Antonescu, C. R.; Landa, J.; Qin, L. X.; Rathbone, D. D.; Condy, M. M.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Ipilimumab for patients with advanced mucosal melanoma
    Journal Article

    Postow, M. A.; Luke, J. J.; Bluth, M. J.; Ramaiya, N.; Panageas, K. S.; Lawrence, D. P.; Ibrahim, N.; Flaherty, K. T.; Sullivan, R. J.; Ott, P. A.; more...
    The Oncologist (2013)

    Fulltext@MSK | Save
  • Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/K-mutated melanoma
    Journal Article

    Catalanotti, F.; Solit, D. B.; Pulitzer, M. P.; Berger, M. F.; Scott, S. N.; Iyriboz, T.; Lacouture, M. E.; Panageas, K. S.; Wolchok, J. D.; Carvajal, R. D.; more...
    Clinical Cancer Research (2013)

    Fulltext@MSK | Save